https://www.selleckchem.com/pr....oducts/Decitabine.ht
543). There was a sustained decline in median Aspergillus IgG levels from baseline, through 6 month to 12 months of continues therapy from 170 (range 20-111 to 121 (range 20-1126), and finally 107 (15-937) mg/l, respectively (P less then .001). Group A patients gained more weight at 6 months (9/15 [60%] vs. 7/33 [21%], P = .012) and at 12 months of treatment (9/15 [60%] vs. 7/33 [22%]), and more patients in Group B lost weight ((13/33 [41%] vs. 1/15 [7%]), P = .015). However, there was no difference in QoL outcomes across groups at
Like
Comment
Share
